Aflatoxin B1 modulates the expression of phenotypic markers and cytokines by splenic lymphocytes of male F344 rats

Journal of Applied Toxicology

Volumn 34, Issue 3, 2014, Pages 241-249

  Qian, Guoqing ^a   Tang, Lili ^a   Guo, Xia ^a   Wang, Franklin ^a   Massey, Michael E ^a   Su, Jianjia ^a   Guo, Tai L ^a   Williams, Jonathan H ^b   Phillips, Timothy D ^c   Wang, Jia Sheng ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Aflatoxin B1; Cytokine; Lymphocyte; Spleen; Surface marker expression

Indexed keywords

AFLATOXIN B1; GAMMA INTERFERON; INTERLEUKIN 4; LYMPHOCYTE SURFACE MARKER; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SUSPENSION; CONTROLLED STUDY; CYTOKINE RELEASE; FISCHER 344 RAT; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPLEEN LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE; ORAL DRUG ADMINISTRATION; POLLUTANT; SPLEEN; SURFACE MARKER EXPRESSION;

ANIMALIA; RATTUS;

AFLATOXIN B1; CYTOKINE; LYMPHOCYTE; SPLEEN; SURFACE MARKER EXPRESSION;

ADMINISTRATION, ORAL; AFLATOXIN B1; ANIMALS; B-LYMPHOCYTES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FLOW CYTOMETRY; KILLER CELLS, NATURAL; LYMPHOCYTES; MALE; PHENOTYPE; RATS; RATS, INBRED F344; SPLEEN; T-LYMPHOCYTE SUBSETS;

EID: 84892979564     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2866     Document Type: Article

References (40)

1. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. 1990. Cytokines: coordinators of immune and inflammatory responses. Annu. Rev. Biochem. 59: 783-836.
2. Bondy GS, Pestka JJ. 2000. Immunomodulation by fungal toxins. J. Toxicol. Environ. Health B Crit. Rev. 3: 109-143.
3. Bruneau JC, Stack E, O'Kennedy R, Loscher CE. 2012. Aflatoxins B(1), B(2) and G(1) modulate cytokine secretion and cell surface marker expression in J774A.1 murine macrophages. Toxicol. In Vitro 26: 686-693.
4. Daniel JH, Lewis LW, Redwood YA, Kieszak S, Breiman RF, Flanders WD, Bell C, Mwihia J, Ogana G, Likimani S, Straetemans M, McGeehin MA. 2011. Comprehensive assessment of maize aflatoxin levels in Eastern Kenya, 2005-2007. Environ. Health Perspect. 119: 1794-1799.
5. Dugyala RR, Sharma RP. 1996. The effect of aflatoxin B1 on cytokine mRNA and corresponding protein levels in peritoneal macrophages and splenic lymphocytes. Int. J. Immunopharmacol. 18: 599-608.
6. Eckmann L, Morzycka-Wroblewska E, Smith JR, Kagnoff MF. 1992. Cytokine-induced differentiation of IgA B cells: studies using an IgA expressing B-cell lymphoma. Immunology 76: 235-241.
7. Elmore SA. 2006. Enhanced histopathology of the spleen. Toxicol. Pathol. 34: 648-655.
8. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, Li-Weber M. 2002. IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity 17: 703-712.
9. Groopman JD, Zhu JQ, Donahue PR, Pikul A, Zhang LS, Chen JS, Wogan GN. 1992. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res. 52: 45-52.
10. Hatori Y, Sharma RP, Warren RP. 1991. Resistance of C57Bl/6 mice to immunosuppressive effects of aflatoxin B1 and relationship with neuroendocrine mechanisms. Immunopharmacology 22: 127-136.
11. Hinton DM, Myers MJ, Raybourne RA, Francke-Carroll S, Sotomayor RE, Shaddock J, Warbritton A, Chou MW. 2003. Immunotoxicity of aflatoxin B1 in rats: effects on lymphocytes and the inflammatory response in a chronic intermittent dosing study. Toxicol. Sci. 73: 362-377.
12. IARC. 1993. Aflatoxins. IARC Monogr. Eval. Carcinog. Risks Hum. 56: 245-395.
13. Jiang H, Chess L. 2000. The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu. Rev. Immunol. 18: 185-216.
14. Jiang Y, Jolly PE, Preko P, Wang JS, Ellis WO, Phillips TD, Williams JH. 2008. Aflatoxin-related immune dysfunction in health and in human immunodeficiency virus disease. Clin. Dev. Immunol. 2008: 790309.
15. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. 2011. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol. Sci. 120(Suppl 1): S28-48.
16. Kizaki T, Kobayashi S, Ogasawara K, Day NK, Good RA, Onoe K. 1991. Immune suppression induced by protoscoleces of Echinococcus multilocularis in mice. Evidence for the presence of CD8dull suppressor cells in spleens of mice intraperitoneally infected with E. multilocularis. J. Immunol. 147: 1659-1666.
17. Kurokouchi K, Kambe F, Yasukawa K, Izumi R, Ishiguro N, Iwata H, Seo H. 1998. TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J. Bone Miner. Res. 13: 1290-1299.
18. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP Jr. 2010. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 116: 4192-4201.
19. Marin DE, Taranu I, Bunaciu RP, Pascale F, Tudor DS, Avram N, Sarca M, Cureu I, Criste RD, Suta V, Oswald IP. 2002. Changes in performance, blood parameters, humoral and cellular immune responses in weanling piglets exposed to low doses of aflatoxin. J. Anim. Sci. 80: 1250-1257.
20. Meissonnier GM, Pinton P, Laffitte J, Cossalter AM, Gong YY, Wild CP, Bertin G, Galtier P, Oswald IP. 2008. Immunotoxicity of aflatoxin B1: impairment of the cell-mediated response to vaccine antigen and modulation of cytokine expression. Toxicol. Appl. Pharmacol. 231: 142-149.
21. Moon EY, Rhee DK, Pyo S. 1999a. In vitro suppressive effect of aflatoxin B1 on murine peritoneal macrophage functions. Toxicology 133: 171-179.
22. Moon EY, Rhee DK, Pyo S. 1999b. Inhibition of various functions in murine peritoneal macrophages by aflatoxin B1 exposure in vivo. Int. J. Immunopharmacol. 21: 47-58.
23. Morris DL, Komocsar WJ. 1997. Immunophenotyping analysis of peripheral blood, splenic, and thymic lymphocytes in male and female rats. J. Pharmacol. Toxicol. Methods 37: 37-46.
24. Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y. 1997. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 89: 1621-1628.
25. Pestka JJ. 2008. Mechanisms of deoxynivalenol-induced gene expression and apoptosis. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 25: 1128-1140.
26. Qian G, Tang L, Liu W, Wang JS. 2010. Development of a non-antibody method for rapid detection of serum aflatoxin B1-lysine adduct. Toxicologist 114: 248.
27. Reddy RV, Sharma RP. 1989. Effects of aflatoxin B1 on murine lymphocytic functions. Toxicology 54: 31-44.
28. Reddy RV, Taylor MJ, Sharma RP. 1987. Studies of immune function of CD-1 mice exposed to aflatoxin B1. Toxicology 43: 123-132.
29. Sabbioni G, Skipper PL, Buchi G, Tannenbaum SR. 1987. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 8: 819-824.
30. Sander B, Hoiden I, Andersson U, Moller E, Abrams JS. 1993. Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J. Immunol. Methods 166: 201-214.
31. Scott TR, Rowland SM, Rodgers RS, Bodine AB. 1991. Genetic selection for aflatoxin B1 resistance influences chicken T-cell and thymocyte proliferation. Dev. Comp. Immunol. 15: 383-391.
32. Sharma RP. 1993. Immunotoxicity of mycotoxins. J. Dairy Sci. 76: 892-897.
33. Taranu I, Marin DE, Bouhet S, Pascale F, Bailly JD, Miller JD, Pinton P, Oswald IP. 2005. Mycotoxin fumonisin B1 alters the cytokine profile and decreases the vaccinal antibody titer in pigs. Toxicol. Sci. 84: 301-307.
34. Teti G, Mancuso G, Tomasello F. 1993. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect. Immun. 61: 227-235.
35. Thaxton JP, Tung HT, Hamilton PB. 1974. Immunosuppression in chickens by aflatoxin. Poult. Sci. 53: 721-725.
36. Torres-Nagel N, Kraus E, Brown MH, Tiefenthaler G, Mitnacht R, Williams AF, Hunig T. 1992. Differential thymus dependence of rat CD8 isoform expression. Eur. J. Immunol. 22: 2841-2848.
37. Turner PC, Moore SE, Hall AJ, Prentice AM, Wild CP. 2003. Modification of immune function through exposure to dietary aflatoxin in Gambian children. Environ. Health Perspect. 111: 217-220.
38. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
39. Wogan GN, Kensler TW, Groopman JD. 2012. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 29: 249-257.
40. Yui MA. 2000. Introcellular Cytokine Detection. In Living Color: Protocols in Flow Cytometry and Cell Sorting, Diamond RA, DeMaggio S (eds). Springer: New York; 552-559.